Status:
UNKNOWN
Pentoxifylline in the Treatment of NEC in Premature Neonates
Lead Sponsor:
Shaare Zedek Medical Center
Conditions:
Necrotizing Enterocolitis
Eligibility:
All Genders
Phase:
PHASE2
Brief Summary
Pentoxifylline improves microcirculation and decreases TNF alpha levels associated with sepsis, rendering it of potential therapeutic value in necrotizing enterocolitis in premature neonates.
Detailed Description
Preterm neonates with a clinical suspicion of necrotizing enterocolitis (NEC) will potentially be candidates for study. After obtaining parental consent, the infants will be prospectively and randomly...
Eligibility Criteria
Inclusion
- Preterm infants \<1750 gm. birth weight
- Abdominal x-ray consistent with NEC (dilated loops, bowel wall edema, fixed or persistent dilated loop with (or without pneumatosis)
Exclusion
- Abdominal perforation
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2010
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00271336
Start Date
January 1 2005
End Date
March 1 2010
Last Update
May 23 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shaare Zedek Medical Center
Jerusalem, Israel, 91031